# US 2014/0271636 A1 · Formulation of an antibody and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271636 A1
- Document ID: US20140271636A1
- Status: Published application
- Kind: A1
- Application number: 14/215,816
- Filed: 2014-03-17
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Takeda GmbH
- Applicants: Takeda GmbH
- Inventors: Markus RAST; Wolfgang ISE; Gerhard BECKER; Peter SKUFCA; Henning GIESELER
- Web page: https://patentgrep.com/patent/US20140271636A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 16/2887: {against CD20}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.

## Claims

### Claim 1

A method for providing a lyophilized formulation of an anti-CD 20 antibody, comprising the steps of:
I) providing a solution comprising the anti-CD 20 antibody,
II) freezing the antibody solution,
III) subjecting the antibody solution to at least one drying step at a shelf temperature of −10° C. to 30° C., in order to obtain the lyophilized formulation,
wherein the lyophilized formulation has a residual moisture content in the range of 1% to 10%.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the antibody solution is subjected to one drying step.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising subjecting the antibody solution to a second drying step, wherein the shelf temperature used in the second drying step is lower than the shelf temperature used in the first drying step.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the shelf temperature used in the second drying step is at least 2° C. lower than the shelf temperature used in the first drying step.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the shelf temperature used in the first drying step is 8° C. and/or the shelf temperature used in the second drying step is 5° C.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the solution provided in step (I) comprises a buffering agent.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the solution provided in step (I) comprises a tonicity modifying agent.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the solution provided in step (I) comprises a surfactant.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the solution provided in step (I) has a pH value in the range of 5.0 to 7.0.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the solution provided in step (I) comprises
a) at least 40 mg/g anti-CD 20 antibody,
b) 5-15 mM histidine,
c) 100-150 mM sucrose,
d) 0.05-0.5 mg/g polysorbate 20; and
wherein the solution provided in step (I) has a pH value of 5.5±0.3.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the anti-CD 20 antibody is Veltuzumab or a fragment thereof.

### Claim 12 (depends on 1)

A method for providing a liquid formulation of an anti-CD 20 antibody, comprising providing a lyophilized formulation according to the method of claim 1, and subsequently performing a step IV) of reconstituting the lyophilized formulation.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the liquid formulation obtained in step IV) comprises
a) at least 80 mg/mL anti-CD 20 antibody,
b) 10-40 mM buffering agent,
c) 200-400 mM tonicity modifying agent, optionally sucrose,
d) 0.2-0.5 mg/mL surfactant,
and wherein the liquid formulation has a pH value of 5.5±0.3.

### Claim 14 (depends on 12)

A reconstituted formulation obtained by the method according to claim 12.

### Claim 15

A lyophilized formulation comprising an anti-CD 20 antibody wherein the lyophilized formulation has a residual moisture content in the range of 1% to 10%.

### Claim 16 (depends on 15)

The lyophilized formulation according to claim 15, further comprising a buffering agent.

### Claim 17 (depends on 15)

The lyophilized formulation according to claim 15, further comprising a tonicity modifying agent.

### Claim 18 (depends on 15)

The lyophilized formulation according to claim 15, further comprising a surfactant.

### Claim 19 (depends on 1)

A lyophilized formulation prepared according to the method of claim 1, comprising an anti-CD 20 antibody.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A method of treating a patient comprising
(i) providing a lyophilized formulation of an anti-CD2O antibody prepared according to the method of claim 1,
(ii) reconstituting the lyophilized formulation, and
(iii) administering the reconstituted formulation to a patient.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the patient has cancer or a non-malignant disease.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the non-malignant disease is rheumatoid arthritis, systemic lupus erythematosum and/or pemphigus.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the patient is suffering from one or more diseases selected from the group consisting of Burkitt Lymphoma, Epstein-Barr Virus Infections, B-Cell Leukemia, Chronic Lymphocytic B-Cell Leukemia, Acute Lymphoblastic Leukemia, Lymphoid Leukemia, Prolymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma, B-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Immunoblastic Large-Cell Lymphoma, Mantle-Cell Lymphoma, Non-Hodgkin Lymphoma, Lymphomatoid Granulomatosis, Plasma Cell Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, Waldenstrom Macroglobulinemia, Immunoproliferative Disorders, Prolymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immunoblastic Large-Cell Lymphoma, Mantle-Cell Lymphoma, Lymphomatoid Granulomatosis, Lymphoproliferative Disorders, Paraproteinemias, Precursor Cell Lymphoblastic Leukemia-Lymphoma, idiopathic thrombocytopenia purpura, Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura, Blood Coagulation Disorders, Blood Platelet Disorders, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Hemostatic Disorders, Lymphatic Diseases, Purpura, Thrombocytopenia, Thrombotic Microangiopathies, Haemostatic Disorders, Vascular Diseases, Rheumatoid Arthritis, Rheumatic Diseases, Connective Tissue Diseases, Pemphigus, systemic lupus erythematosum, Herpesviridae Infections, and DNA Virus Infections.
